GLP-1 Receptor Agonists for Type 2 Diabetes Management

Introduction to GLP-1 Receptor Agonists

The American Diabetes Association recommends the use of GLP-1 receptor agonists for type 2 diabetes management, with long-acting agents demonstrating superior efficacy for HbA1c reduction and fasting glucose control 1, 2

GLP-1 receptor agonists enhance insulin secretion and inhibit glucagon secretion in a glucose-dependent manner, delay gastric emptying, and reduce food intake through central appetite suppression, with semaglutide demonstrating the greatest glucose-lowering efficacy 1, 2
The European Association for the Study of Diabetes suggests that long-acting agents have more profound effects on overnight and fasting plasma glucose and HbA1c reduction, while short-acting agents maintain greater effects on postprandial glucose control 2

The American College of Cardiology recommends the use of GLP-1 receptor agonists with proven cardiovascular benefit, such as liraglutide, semaglutide, and dulaglutide, for patients with type 2 diabetes and established atherosclerotic cardiovascular disease 4, 5
The National Kidney Foundation suggests that GLP-1 receptor agonists with proven cardiovascular benefit are recommended for patients with type 2 diabetes and chronic kidney disease who do not meet glycemic targets with metformin and/or SGLT2 inhibitors, reducing albuminuria and slowing eGFR decline 5

The American Diabetes Association notes that GLP-1 receptor agonists have minimal risk for hypoglycemia when used as monotherapy due to their glucose-dependent mechanism of action, but the risk increases when combined with insulin or insulin secretagogues 2, 5
The European Medicines Agency warns that GLP-1 receptor agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and treatment is not recommended in patients at risk for thyroid C-cell tumors, pancreatic cancer, or pancreatitis based on theoretical risks 5